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Through its role in polyamine acetylation and the back-conversion pathway, spermidine&ermine N’-acetyltransferase (SSAT) has the potential 
to control intracellular polyamine pools by facilitating their catabolism and/or excretion. The possibility that the enzyme is subject to regulation 
by intracellular polyamine pools was investigated in MALME3 human melanoma cells. Increases in intracellular polyamine pools by treatment 
with 3 PM exogenous permidine or spermine for 48 h caused SSAT activity to increase 111% and 22696, respectively, and SSAT-specific mRNA 
to rise 19% and 6646, respectively. Decreases in polyamine pools by treatment with inhibitors of polyamine biosynthesis caused SSAT activity to 
decrease by 46% and mRNA to fall by 89%. Both SSAT activity and mRNA were more sensitive to changes in spermine than spermidine. The 
identification of a positive regulatory relationship between SSAT and intracellular polyamine pools further implicates this enzyme in a proposed 
model for polyamine pool homeostasis. 
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1. INTRODUCTION 
Under steady-state growth conditions, the intracellu- 
lar polyamine pools of any given cell type are main- 
tained within a relatively narrow range, the upper limits 
seemingly determined by the potential cellular toxicity 
of polyamine excess and the lower limits by the polyam- 
ine requirement for cell growth. To a large degree, this 
range is controlled by changes in polyamine biosynthe- 
sis and uptake, both of which are negatively regulated 
by intracellular polyamine pools [l-3]. Through their 
respective functions, uptake and biosynthesis have the 
potential to actively raise polyamine pools. The pol- 
yamine acetylating enzyme, spermidine/spermine N’- 
acetyltransferase (SSAT), serves as a rate-limiting step 
in a polyamine back-conversion pathway [4]. Because 
polyamine acetylation and the back-conversion path- 
way facilitate polyamine excretion and catabolism [4-61, 
respectively, SSAT has the potential to participate in 
Correspondence address: C.W. Porter, Grace Cancer Drug Center, 
Roswell Park Cancer Institute, Ehn and Carlton Streets, Buffalo, NY 
14263, USA. Fax: (1) (716) 845-8857. 
Abbreviations: AMA, S-(5’-deoxy-5-adenosyl)-methylthioethyl- 
hydroxylamine; DFMO, a-difluoromethylomithine; ODC, omithine 
decarboxylase; PUT, putrescine; SAMDC, S-adenosylmethionine d - 
carboxylase; SPD, spermidine; SPM, spermine; SSAT, spermidinel 
spermine-N’acetyltransferase. 
polyamine pool homeostasis by lowering intracellular 
polyamine pools [5]. 
At present, the regulatory relationship between intra- 
cellular polyamine pools and SSAT gene expression is 
not well defined. SSAT activity is known to be inducible 
by increases in intracellular polyamine pools [7-g]. 
More impressive increases in SSAT activity are pro- 
duced with structurally similar analogs of polyamines 
[8-121. Analog-induced increases in SSAT activity have 
recently been found to be accompanied by the accumu- 
lation of SSAT-specific mRNA [13-161. In this report, 
we demonstrate that the natural polyamines can medi- 
ate increases and decreases in SSAT activity and 
mRNA levels. These findings further substantiate a 
probable cellular role for SSAT in polyamine pool ho- 
meostasis. Portions of this work have been reported in 
abstract form [17]. 
2. EXPERIMENTAL 
The human melanoma cell line, MALME3M, was chosen for study 
because of its extreme SSAT inducibility by polyamine analogs [12,18]. 
Cells were grown as monolayers in RPM1 1640 medium (G&co, 
Grand Island, NY) containing 10% NuSerum (Collaborative Re- 
search Products, Bedford, MA), 2% HEPEYMOPS buffer, 60 U/ml 
penicillin and 60 &ml streptomycin. Cells were treated with polyam- 
ines and/or inhibitors 24 h after plating. In experiments where polyam- 
ines were added, the medium was supplemented with 1 mM aminogua- 
nidine to inhibit serum amine oxidase [19]. 
The relationship between intracellular polyamines and SSAT activ- 
ity and mRNA levels was evaluated by selectively increasing and 
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decreasing individual polyamine pools. PUT was found to have a 
minimal regulatory effect on SSAT activity or mRNA (data not 
shown). Pools were increased by treatment with 3 pM exogenous SPD 
or SPM for 48 h and decreased by treatment with specific and irrevers- 
ible inhibitors of polyamine biosynthetic enzymes in the presence and 
absence of exogenous polyamines. Typically, the ODC inhibitor, 
DFMO (at 1 mM), depletes PUT and SPD pools [20], and the 
SAMDC inhibitor, AMA (at 0.1 mM) elevates PUT pools and lowers 
SPD and/or SPM pools [21]. Addition of SPD or SPM (at 3 PM to 
avoid toxicity) to the combination of DFMO and AMA selectively 
augmented those particular polyamine pools. Cells were treated with 
the inhibitors for 48 h. 
SSAT activity was measured via biochemical assay as previously 
described [22]. It should be noted that this enzyme assay also detects 
other non-specific acetylase activities which, under basal conditions, 
account for about 70% of the total measured activity in MALME-3M 
cells, as determined by immuno-precipitation [12]. Polyamine pools 
were determined on perchloric acid cell extracts using a high perform- 
ance liquid chromatography system described elsewhere [12]. 
RNA was extracted with guanidinium isothiocyanate on cesium 
chloride gradients, electrophoresed with ethidiurn bromide on 1.5% 
agarose formaldehyde gels, transferred to Duralon membrane (Strat- 
agene, LaJolla, CA), crosslinked (Stratagene) and probed with 32P- 
labeled human SSAT cDNA (provided courtesy of R. Casero Jr., 
Johns Hopkins Oncology Center, Baltimore, MD; [14,23]). Trans- 
ferred RNA was visualized by UV irradiation to assess the integrity 
of 28 S and 18 S rRNA and uniformity of loading for each sample. 
Northern blots were quantitated by densitometry of phosphoimaging 
analysis (Phosphoimager, Molecular Dynamics, Sunnyvale, CA). 
3. RESULTS 
A comparison of the effects of exogenous polyamines 
on SSAT activity in MALME-3M cells treated for 48 
h revealed that exogenous SPD and SPM increased en- 
zyme activity (Table I) while PUT has a minimal effect 
(data not shown). Treatment with SPD increased SPD 
pools by 47% and SSAT activity by 111% while SPM 
increased SPM pools by 40% and SSAT activity by 
226%. Due to various compensatory responses (see sec- 
tion 4), SPM decreased when SPD increased and vice 
versa, so that the overall polyamine content of treated 
cells remained relatively constant during treatment (i.e. 
2.10-2.25 nmol/106 cells). Both treatments resulted in 
the accumulation of N’-acetylSPD, a product of SSAT, 
indicating that the induced enzyme was functional in the 
cell. The effect of SPM on SSAT activity and N’-ace- 
tylSPD was consistently greater than that of SPD and, 
although subtle, this trend was reinforced by similar 
increases in SSAT mRNA. 
Northern blot analysis of mRNA from treated cells 
revealed three bands which hybridized to the SSAT 
cDNA probe (- 3.5, 1.5 and 1.3 kb). The 3.5 kb SSAT 
transcript was typically found in much lower abundance 
than the 1.5 and 1.3 kb species, and appears to represent 
an unprocessed precursor based on its size similarity to 
the SSAT gene and because it is the most prominent 
mRNA form in nuclear preparations [16]. For the pur- 
pose of quantitating SSAT mRNA levels, densitometric 
measurements of the B and C bands were combined. As 
with SSAT activity, treatment with exogenous SPD or 
SPM consistently increased SSAT mRNA, with SPM 
being the more effective (Fig. 1, Table I). 
In addition to being up-regulated by increases in poly- 
amine pools, SSAT was found to be down-regulated by 
decreases in polyamine pools, as achieved by treatment 
with the ODC inhibitor, DFMO, and the SAMDC in- 
hibitor, AMA. Treatment with 1 mM DFMO depleted 
PUT pools and reduced SPD by 40% while leaving SPM 
pools relatively unaffected (Table I). Under these condi- 
tions of SPD depletion, SSAT activity and mRNA were 
reduced by 37% and 51%, respectively. Treatment with 
AMA increased PUT pools 16.5-fold, and decreased 
SPM pools by 60% while SPD pools were relatively 
unchanged. This treatment produced a 36% reduction 
in SSAT activity and a 74% decrease in SSAT mRNA. 
Thus, inhibiting polyamine biosynthesis decreases 
SSAT activity. It should be noted that since the polyam- 
ine pools following treatment with SPM or 
Table I 
Modulation of polyamine pools, SSAT activity and mRNA in MALME-3M cells 
Treatment 
(48 h) 
PUT 
Polyamine Pools” (nmoY106 cells) 
SPD SPM N ‘-AcSPD 
SSAT activityb 
(% control) 
SSAT RNAd 
(Bands B+C; 
% control) 
Control 
3 pM SPD 
3 PM SPM 
1 .O mM DFMO 
0.1 mM AMA 
AMA+DFMO 
AMA+DFMO+SPD 
AMA+DFMO+SPM 
0.07 + 0.013 
nd’ 
nd 
0.01 f 0.015 
1.19 + 0.107 
0.34 f 0.039 
0.19 * 0.070 
0.01 
0.84 + 0.083 
1.19 + 0.095 
0.32 + 0.032 
0.53 f 0.066 
0.80 + 0.046 
0.92 f 0.072 
2.25 f 0.459 
0.23 
1.26 f 0.023 
1.04 f 0.182 
1.77 f 0.152 
1.55 + 0.271 
0.55 f 0.091 
0.71 f 0.096 
0.45 f 0.106 
1.91 
0.04 + 0.004 
0.94 f 0.362 
0.23 + 0.063 
0.01 f 0.014 
nd 
nd 
0.39 + 0.089 
0.14 
100 100 
211 + 41 119 
326 + 110 166 
63f 1.5 49 
645 12 26 
54 f 10 (100) 19 (100) 
107 f 48 (198) 121 (636) 
303 ? 81 (561) 158 (832) 
“Mean & SD. of 3 flasks; except AMA+DFMO+SPM, mean of 2 flasks. 
bMean f standard deviation from duplicate determinations of 3-5 experiments; control SSAT activity, 44 pmol/min/mg. 
‘nd, not detectable. 
dRelative densitometric scanning of representative Northern blot probed with human SSAT cDNA. 
ePercent of DFMO+AMA value. 
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Fig. 1. Northern blot phosphoimage of MALME-3M human mela- 
noma cells treated for 48 h with exogenous SPD and SPM in the 
presence and absence of the biosynthetic inhibitors, 0.1 mM AMA (A) 
and/or 1.0 mM DFMO (D) (AMA plus DFMO = AD). Blots loaded 
with 15 pg RNA per lane, were probed with human SSAT cDNA. 
Typically, the SSAT cDNA hybridizes with three transcripts [16], but 
in this phosphoimage, bands B and C are not resolved. Values at the 
bottom are based on densitometry of phosphoimage analysis of band 
B/C relative to control RNA (100%). 
DFMO were very similar, the different SSAT responses 
reflect the direction in which the pools were pressured 
to change during treatment. As will be discussed, the 
final polyamine pools represent he net effects of several 
compensatory responses (including that of SSAT). 
In order to further confirm that pool modulation was 
regulating SSAT mRNA and activity, experiments were 
performed in which the inhibitors, DFMO and AMA, 
were used in combination with exogenous SPD and 
SPM to examine the combined effects of polyamine 
depletion with selective pool maintenance. Overall, the 
DFMO/AMA inhibitor combination was far less effec- 
tive in lowering polyamine pools in MALME-3M cells 
than in L1210 leukemia cells where near-total SPD and 
SPM pool depletion has been reported [21]. In part, this 
is probably because the MALME-3M cells have a dou- 
bling time that is 4-fold longer than L1210 cells so that 
during a 48 h incubation, there is less dilution (deple- 
tion) of pools by cell division. In MALME-3M cells, the 
inhibitor combination lowered SPM pools by 56% and 
increased SPD pools by 10% while preventing PUT 
pools from rising by as much as with AMA alone. This 
combination treatment produced the greatest decrease 
in both SSAT activity and mRNA (46% and 81%, re- 
spectively) seen with any treatment. Although greater 
pool perturbations were obtained with individual inhib- 
itors (i.e. AMA), it is again relevant o consider that the 
polyamine pools measured at the end of treatment with 
two inhibitors probably reflect responses which attempt 
to maintain a normal pool profile. Results with the 
inhibitor-polyamine combinations confirmed earlier in- 
dications that, relative to SPD, SPM exhibited a greater 
capacity to induce SSAT. The combination of DFMO, 
AMA and SPD markedly elevated the SPD pool while 
further lowering the SPM pool. Under these conditions, 
SSAT activity increased by 10% while mRNA levels 
increased by 21%. When considered relative to the 
DFMO+AMA combination, these same values in- 
creased to 98% and 536%, respectively. Substitution of 
SPM for SPD in the DFMO+AMA combination low- 
ered intracellular SPD pools further while markedly 
increasing the SPM pool. With this treatment, SSAT 
activity increased by 203%, and mRNA rose by 58%. 
Relative to the DFMO+AMA combination, these val- 
ues increased by 461% and 732%, respectively. These 
trends were consistently obtained in three separate ex- 
periments. Thus, under the combined pressures of poly- 
amine depletion and polyamine excess, the predominant 
SSAT response was in the direction of up-regulation, 
presumably to counter polyamine excess. 
4. DISCUSSION 
SSAT activity was found to be sensitively regulated 
by both increases and decreases in intracellular polyam- 
ine pools. The magnitude of these changes is probably 
underestimated since only about 30% of the basal activ- 
ity (and probably less than that under conditions of 
down-regulation) represents authentic SSAT activity in 
MALME-3M cells [12]. Although increases in SSAT 
activity in response to polyamines have been previously 
reported [7-91, this present study reveals that decreases 
in SSAT activity occur in response to inhibition of poly- 
amine biosynthesis and the subsequent lowering of pol- 
yamine pools. This finding is substantiated by parallel 
decreases in SSAT-specific mRNA. These data indicate 
that, under basal conditions, steady-state levels of 
SSAT expression are probably maintained in a partially 
up-regulated state by basal polyamine pools since a 
decline in these pools results in a decrease in SSAT 
activity and mRNA. Polyamine transport and the poly- 
amine biosynthetic enzymes, ODC and SAMDC, seem 
to be similarly maintained under basal conditions but 
via an inverse relationship since a decline in pools 
causes an increase in their expression [1,26] and vice 
versa [ 1,2]. 
The observation that SSAT induction can be accom- 
panied by increases in mRNA accumulation was first 
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directly demonstrated in studies with the polyamine an- 
alogs which subsequently lead to the cloning of the 
SSAT cDNA from human [14,23], mouse [27] and ham- 
ster [28] sources. This present study illustrates that the 
natural polyamines can also produce increases in SSAT 
mRNA. The significance of this observation is 3-fold: 
(i) it indicates that the observed changes in SSAT activ- 
ity are truly regulatory responses as opposed to direct 
effects on the enzyme; (ii) it strongly suggests aprobable 
role for SSAT in polyamine pool homeostasis (as dis- 
cussed below); and (iii) it confirms that expression of the 
SSAT gene is positively regulated by the natural poly- 
amines at the level of mRNA. This last feature renders 
SSAT unique among known genes. Although the 
steady-state l vels of c-myc and c-fos in COLO 320 cells 
have been shown to decrease with polyamine depletion 
[29], the inverse relationship, whereby mRNA levels 
increase with the addition of polyamines to intact cells, 
has not been demonstrated. Also, when these same cells 
are treated with a polyamine analog, N’ W2- 
bis(ethyl)spermine, which is known to mimic namral 
polyamines in down-regulating ODC [30] and transport 
[31,32] and by up-regulating SSAT [8-121, the steady- 
state mRNA levels of these proto-oncogenes decreases 
instead of increasing [29]. Thus, unlike SSAT, the ex- 
pression of these genes does not appear to be regulated 
by polyamines via a truly positive relationship. The only 
other gene which is known to be positively regulated by 
exogenous polyamines in intact cells is an ODC-binding 
protein termed antizyme, which contributes to the rapid 
degradation of that enzyme [33]. Its induction, however, 
is not mediated by increases in antizyme-specific 
mRNA but by changes at the level of translation [34]. 
As noted above, the nature of the regulatory relation- 
ship between polyamine pools and SSAT gene expres- 
sion, as indicated by activity and mRNA, is distinctly 
positive - as pools increase, SSAT also increases and 
vice versa. The former was apparent from experiments 
with exogenous polyamines and the latter by pool deple- 
tion with specific enzyme inhibitors. The biosynthetic 
enzymes, ODC and SAMDC [l], and the polyamine 
transport system [2,31,32,35], are also sensitively up- 
regulated and down-regulated by changes in intracellu- 
lar polyamine pools. Unlike SSAT, however, the regula- 
tory relationships for these systems are negative in na- 
ture - as pools decrease, enzyme and transport activities 
increase and vice versa. Taken together, these various 
systems can be integrated into a model for polyamine 
homeostasis (Fig. 2) consisting of three key effecters: 
the biosynthetic enzymes (ODC and SAMDC), the 
transport apparatus, and SSAT. All three are character- 
ized by being specific for polyamines, rate-limiting in 
their respective activities and pathways, and by being 
sensitively up-regulated or down-regulated by changes 
in intracellular polyamine pools. The biosynthetic en- 
zymes and the transport system can actively respond to 
polyamine insufficiency by synthesizing and taking-up, 
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Fig. 2. Proposed model for polyamine homeostasis howing the criti- 
cal role of polyamine pools in regulating three homeostatic effecters 
(solid boxes) and the various activities (broken boxes) which the latter 
control. SSAT differs from other effecters in that it has the potential 
to control several activities. Polyamine binding is included among 
these since acetylation reduces the net positive charge of a polyamine 
by one and would therefore be expected to limit its binding capabili- 
ties. The parentheses beside the large arrows indicate the nature of the 
regulatory relationship between the pools and the effector: in a posi- 
tive relationship, the effector is down-regulated when pools go down 
and vice versa; in a negative relationship, the effector is up-regulated 
when pools go down and vice versa. The model predicts that depletion 
of polyamine pools by enzyme inhibitors would up-regulate the puta- 
tive transporter and the biosynthetic enzymes, ODC and/or SAMDC 
(depending on which if either enzyme is targeted by the inhibitor), and 
down-regulate SSAT. By contrast, polyamine xcess, as achieved with 
exogenous polyamines, or apparent polyamine excess, as achieved by 
polyamine analogs, would down-regulate the transporter and biosyn- 
thetic enzymes and up-regulate SSAT. (Reproduced with kind permis- 
sion of Kluwer Academic Publishers, Lancaster, England, from [5].) 
respectively, more polyamines. By contrast, SSAT can 
actively respond to polyamine excess by acetylating 
SPD and SPM and thereby facilitating their excretion 
out of the cell and/or promoting their back-conversion 
to PUT which can be catabolized by various PUT-di- 
rected oxidases [4,6]. These same systems can respond 
passively as follows: during polyamine excess, biosyn- 
thesis and uptake can decrease, and during polyamine 
insufficiency, SSAT-mediated catabolism and excretion 
can decrease. 
It is important o emphasize that the proposed model 
is a working hypothesis which requires additional vali- 
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dation by experimentation. Studies with polyamine ana- 
logs are supportive of the model. Cells treated with such 
analogs respond as though polyamine excess exists, 
namely ODC and SAMDC are down-regulated [12], 
transport is down-regulated [31,32], and SSAT is mark- 
edly up-regulated [8-121. Acetylated polyamines are ex- 
creted into the medium [12,36]. It is interesting to note 
that during treatment with polyamine analogs, intracel- 
lular polyamines are decreased @resumably via halted 
synthesis and increased excretion) as the analog is taken 
up, so that a relatively constant total polyamine content 
(including analog) is maintained by the cells [32,37]. 
These observations would seem to confirm the inte- 
grated potential of the various responses in polyamine 
pool homeostasis. 
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